kearny
Victor Dzau, M.D.

Dr. Dzau is Chancellor for Health Affairs at Duke University and President and CEO of the Duke University Health System since July 2004. He is also James B. Duke Professor of Medicine and Director of Molecular and Genomic Vascular Biology at Duke. Prior to coming going to Duke, he served as Hersey Professor of Medicine at Harvard Medical School and Chairman of the Department of Medicine at Brigham and Women's Hospital in Boston Massachusetts from 1996 to 2004. Prior to his work at Harvard and Brigham and Women's, he served as Arthur Bloomfield Professor and Chairman of the Department of Medicine at Stanford.

Dr. Dzau is a member of the Institute of Medicine of the National Academy of Sciences and the European Academy of Science and Arts. He was the previous Chairman of the National Institutes of Health (NIH) Cardiovascular Disease Advisory Committee and he served on the Advisory Committee of the Director of NIH.

Dr. Dzau received the first Hatter Award from the Medical Research Council of South Africa in 2000. He was awarded the prestigious Gustav Nylin Medal by the Swedish Royal College of Medicine and the Swedish Cardiology Society, the Novartis Award for Hypertension Research by the American Heart Association (which also named him one of its Distinguished Scientists for 2004), the 2004 Max Delbruck Medal by the Max Delbruck Center for Molecular Medicine, Berlin, Germany, the 2005 Golden Door Award by the International Institute of Boston, and a 2005 Ellis Island Medal of Honor by the National Ethnic Coalition of Organizations.

Dr. Dzau is a Director at Pepsico Inc, Genzyme (Nasdaq:GENZ), Alnylam (Nasdaq: ALNY) and Medtronic (Nasdaq: MDT) and serves on the Scientific Advisory Board of CV Therapeutics (Nasdaq:CVTX), Atherogenics Inc. (Nasdaq:AGIX) and United Therapeutics (Nasdaq:UTHR).

Dr. Dzau received his M.D. from McGill University in Montreal and underwent postgraduate training at the Brigham and Women's Hospital in Boston.